Better glycaemic control for 30,171 insulin-naive patients with type 2 diabetes after starting biphasic insulin aspart 30/70 (BIAsp 30) therapy:: IMPROVE™ study subgroup analysis

被引：0
|
作者：
Kawamori, R. [1 ]
Srishyla, M. V. [2 ]
Wenying, Y. [3 ]
机构：
[1] Juntendo Univ, Sch Med, Dept Metab & Endocrinol, Tokyo 113, Japan
[2] Novo Nordisk AS, Virum, Denmark
[3] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
978
引用
收藏
页码：S393 / S394
页数：2
相关论文
共 50 条
  • [21] Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes
    Velojic-Golubovic, M.
    Mikic, D.
    Pesic, M.
    Dimic, D.
    Radenkovic, S.
    Antic, S.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (01) : 23 - 27
  • [22] IMPROVE (TM) observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus
    Kawamori, Ryuzo
    Valensi, Paul
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 507 - 516
  • [23] Efficacy of biphasic insulin aspart 70/30 in insulin-naive patients with type 2 diabetes mellitus not achieving glycemic targets on oral antidiabetic agents
    Garber, Alan J.
    Jain, Rajeev
    Wahl, Timothy
    Moses, Alan
    Cao, Anjun
    Bressler, Peter
    DIABETES, 2006, 55 : A477 - A477
  • [24] Use of a New Basal Insulin with a Bolus Boost (IDegAsp) in Type 2 Diabetes: Comparison with Biphasic Insulin Aspart 30 (BIAsp 30)
    Vaag, Allan
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine V.
    Niskanen, Leo
    DIABETES, 2011, 60 : A313 - A313
  • [25] Thrice-daily injections of biphasic insulin aspart 30 (NovoMix® 70/30) improves glycaemic control in patients with type 1 diabetes
    Chen, JW
    Lauritzen, T
    Bojesen, A
    Christiansen, J
    DIABETOLOGIA, 2005, 48 : A330 - A330
  • [26] Treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients: long-term effects on diabetesrelated complications
    Lammert, M
    Palmer, AJ
    Roze, S
    Valentine, WJ
    DIABETOLOGIA, 2005, 48 : A308 - A309
  • [27] In inadequately controlled patients with Type 2 diabetes, Biphasic Insulin Aspart 30 combined with Pioglitazone provides better glycaemic control than Biphasic Insulin Aspart 30 monotherapy or Pioglitazone/Sulphonylurea combination.
    Raz, I
    Stranks, S
    Filipczak, R
    Joshi, P
    Lertoft, B
    Råstam, J
    Chow, FC
    DIABETOLOGIA, 2003, 46 : A8 - A8
  • [28] Effect of BIAsp 30 (biphasic insulin aspart 30) in combination with oral hypoglycaemic agents on glycaemic regulation in non-obese patients with type 2 diabetes
    Lund, S. S.
    Tarnow, L.
    Nielsen, B. B.
    Hansen, B. V.
    Pedersen, O.
    Parving, H. -H.
    Vaag, A. A.
    DIABETOLOGIA, 2006, 49 : 600 - 600
  • [29] Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study
    Valensi, P.
    Benroubi, M.
    Borzi, V.
    Gumprecht, J.
    Kawamori, R.
    Shaban, J.
    Shah, S.
    Shestakova, M.
    Wenying, Y.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (03) : 522 - 531
  • [30] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    DIABETOLOGIA, 2018, 61 : S410 - S411
12345